Disease landscape

Triple-Negative Breast Cancer clinical trials

Get alerts when Triple-Negative Breast Cancer trials change

510 active trials 284 recruiting 57 Phase 3 296 sponsors 90 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 62 of 90 changes on 20 trials

2026-08-13
Trial status changed: Recruiting → Withdrawn
Trial withdrawn: no patients were able to be enrolled
Enrollment reduced: 30 → 0 participants
Primary completion pushed: 2026-06-30 → 2026-08-10
Completion pushed: 2026-06-30 → 2026-08-10
NCT06610097 TNBC Gut Microbiota During Neoadjuvant Treatment · Scripps Health
2026-09-05
Primary completion pushed: 2027-02 → 2029-06
Primary endpoint(s) modified
Enrollment increased: 495 → 575 participants
Interventions modified
Completion pushed: 2027-04 → 2029-06
Trial arms changed: 9 → 11
NCT06400472 A Study of Sofe-M in Participants With Selected Advanced Solid Tumors · Eli Lilly and Company · Phase 1
2026-09-04
Primary completion pushed: 2026-04 → 2026-12
Enrollment closed, study ongoing
Completion pushed: 2026-04 → 2026-12
NCT06337084 Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors · Monopar Therapeutics · Phase 1
2026-09-03
Primary completion pushed: 2026-03 → 2027-03
Completion pushed: 2026-03 → 2027-03
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy… · AbbVie · Phase 1
2026-09-01
Primary completion pushed: 2026-07-01 → 2027-07-01
Completion pushed: 2026-10-01 → 2027-10-01
NCT06460298 ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative… · ProDa BioTech, LLC · Phase 1/2
2026-09-02
Primary completion pushed: 2027-01-01 → 2028-01-01
Completion pushed: 2027-01-01 → 2028-01-01
NCT03401385 First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) · Daiichi Sankyo Co., Ltd. · Phase 1
2026-09-05
Primary completion pushed: 2025-09-10 → 2027-09-10
Completion pushed: 2025-12-01 → 2027-12-01
NCT05192798 Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of… · The First Affiliated Hospital of Bengbu Medical University · Phase 2
2026-09-04
Primary completion pushed: 2026-12 → 2027-12
Primary endpoint(s) modified
Interventions modified
Completion pushed: 2026-12 → 2027-12
NCT05846789 Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast… · Kathy Miller · Phase 2
2026-09-03
Primary completion pushed: 2028-12-30 → 2030-12-30
Primary endpoint(s) modified
Phase changed: Phase 1 → Phase 1/2
Enrollment increased: 124 → 280 participants
Interventions modified
Trial sites expanded: 7 → 10 locations
Completion pushed: 2029-12-30 → 2031-12-30
Trial arms changed: 2 → 3
NCT05868226 PRE-ISPY Phase I/II Oncology Platform Program · QuantumLeap Healthcare Collaborative · Phase 1/2
2026-08-29
Primary completion pushed: 2026-08 → 2026-12
Completion pushed: 2026-08 → 2026-12
NCT04677816 Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in… · Wake Forest University Health Sciences · Phase 2
2026-08-29
Primary completion pushed: 2026-07 → 2027-07
Enrollment closed, study ongoing
Completion pushed: 2026-07 → 2027-07
NCT04427293 Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer… · University of Illinois at Chicago · Phase 1
2026-08-14
Primary completion pushed: 2026-10-01 → 2027-06-01
Enrolling by invitation only
NCT06910072 Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and… · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2/3
2026-08-21
Primary completion pushed: 2026-09 → 2027-08
Completion pushed: 2027-03 → 2027-08
NCT06027268 Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic… · Wake Forest University Health Sciences · Phase 2
2026-08-13
Primary completion pushed: 2026-07 → 2026-11
NCT04768426 Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early… · Stanford University · Phase 2
2026-08-18
Primary completion pushed: 2028-08 → 2030-08
Completion pushed: 2028-08 → 2030-08
NCT04861077 Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission… · University of Alabama at Birmingham · Early Phase 1
2026-08-22
Primary endpoint(s) modified
Recruitment opened
Enrollment increased: 56 → 299 participants
Trial sites expanded: 0 → 3 locations
Primary completion moved earlier: 2028-08 → 2027-08
Trial arms changed: 2 → 3
NCT07623369 A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors · Huahui Health · Phase 1
2026-08-21
Primary endpoint(s) modified
Trial arms changed: 4 → 5
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for… · Mayo Clinic · Phase 1/2
2026-08-19
Enrollment reduced: 120 → 65 participants
Trial completed
Primary completion moved earlier: 2026-06-30 → 2026-04-20
Completion moved earlier: 2026-12-31 → 2026-05-29
NCT06685796 A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced… · BeBetter Med Inc · Phase 2
2026-08-07
Enrollment reduced: 450 → 165 participants
Enrollment closed, study ongoing
Trial sites reduced: 41 → 36 locations
NCT05581004 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single… · Genentech, Inc. · Phase 1
2026-09-04
Enrollment closed, study ongoing
NCT06617169 Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors · Monopar Therapeutics · Phase 1

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07786428 Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC University of Texas Southwestern Medical Center new Phase 2
2026-08-13 NCT07762703 Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic… BreakBio Corp new Phase 1/2
2026-08-04 NCT07743723 A Study of IOV-5001 in Adults With Advanced Solid Tumors Iovance Biotherapeutics new Phase 1/2
2026-07-28 NCT07730125 Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory… CoRegen, Inc. new Phase 1/2
2026-07-23 NCT07723469 Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing… SURGE Therapeutics new Phase 3
2026-07-20 NCT07714382 Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer Sohag University new
2026-07-15 NCT07705334 A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic… SHY Therapeutics new Phase 1
2026-07-07 NCT07687446 Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative… Assistance Publique - Hôpitaux de Paris new
2026-07-02 NCT07681297 Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors… National University Hospital, Singapore new Phase 1/2
2026-07-01 NCT07679360 A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's… Suzhou Suncadia Biopharmaceuticals Co., Ltd. new Phase 3

Active trials by phase

Early Phase 1
12
Phase 1
91
Phase 1/2
73
Phase 2
184
Phase 2/3
3
Phase 3
54
Phase 4
3
Not charted: 90 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 510

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT06920810 Viscum Album for TNBC on Adjuvant Pembrolizumab Ilsan Cha hospital Recruiting 2025-04-10
NCT04790305 Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative… Fudan University Recruiting 2024-06-27
NCT05843292 Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy… Shanghai Jiao Tong University School of Medicine Not Yet Recruiting 2023-06-06
Phase 3
NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not… Merck Sharp & Dohme LLC Recruiting 2026-09-03
NCT06841354 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination… Merck Sharp & Dohme LLC Recruiting 2026-09-03
NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast… Merck Sharp & Dohme LLC Recruiting 2026-09-03
NCT05812807 Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a… Alliance for Clinical Trials in Oncology Recruiting 2026-08-05
NCT06081244 NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk… West German Study Group Recruiting 2026-08-03
NCT06606730 Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early… UNICANCER Recruiting 2026-07-23
NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's… Gilead Sciences Recruiting 2026-07-15
NCT06279364 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable… Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recruiting 2026-05-08
NCT06889688 Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in… Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting 2026-04-23
NCT07533123 A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With… Jiangsu Alphamab Biopharmaceuticals Co., Ltd Recruiting 2026-04-16
NCT05806060 Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally… Fudan University Recruiting 2026-03-25
NCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally… Akeso Recruiting 2026-03-16
NCT06627712 SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC West China Hospital Recruiting 2026-01-30
NCT05909332 Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant… Fudan University Recruiting 2026-01-21
NCT07111832 A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. Recruiting 2025-12-18
NCT04722978 Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic… Sun Yat-Sen University Cancer Center Recruiting 2025-12-17
NCT05929768 Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative… SWOG Cancer Research Network Recruiting 2025-11-05
NCT06732323 A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative… Qilu Pharmaceutical Co., Ltd. Recruiting 2025-09-23
NCT05862064 A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined… Fudan University Recruiting 2025-07-16
NCT03671044 A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in… Jina Pharmaceuticals Inc. Recruiting 2025-03-21
NCT06533384 PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC Guangdong Provincial People's Hospital Recruiting 2024-11-04
NCT05999149 A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as… Fudan University Recruiting 2024-02-21
See all 510 active Triple-Negative Breast Cancer trials with filters →

Top sponsors by active trials in this area

Fudan University (35) · National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (13) · Memorial Sloan Kettering Cancer Center (8) · UNICANCER (8) · Tianjin Medical University Cancer Institute and Hospital (7) · Gilead Sciences (6) · H. Lee Moffitt Cancer Center and Research Institute (6) · Novartis Pharmaceuticals (6) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (6)

Get alerts when Triple-Negative Breast Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free